Pelosi also said it's "irrelevant" whether approving the USMCA trade deal would give President Donald Trump a victory ahead of the 2020 election.Politicsread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
General Motors stands to lose hundreds of millions of dollars in lost production as a United Auto Workers union strike against the automaker enters its second day, but Wall...Autosread more
Damage to the top OPEC producer's oil facilities ignited fears of supply disruption around the world and has sent crude prices soaring.Energyread more
The second-largest investor in Kraft Heinz Company discloses that it has again trimmed its stake in the food company.Marketsread more
"That leads the developed world to say to China: 'We've got to rebalance this. It's working for you. It's not working for us,'" says the billionaire Blackstone co-founder.Economyread more
Microsoft founder Bill Gates takes an aggressive approach to investing, despite being the second richest person in the world.Wealthread more
According to a new report, consumers ages 14 to 24 overwhelmingly prefer physical stores for shopping, largely for mental health reasons.Retailread more
These are the stocks posting the largest moves in midday trading.Market Insiderread more
Viacom chief executive officer Bob Bakish is not worried about competition in the streaming space, on the heels of its merger with CBS.The Faber Reportread more
Consumers could pay an average 15 to 20 cents more per gallon for unleaded gas by the end of the month following the attack on Saudi oil installations.Market Insiderread more
Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene, the biggest acquisition announced so far this year.
The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol's balance sheet while assuming $20 billion in Celgene's debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.
Now, hedge funds Wellington Management and Starboard Value say the deal doesn't sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.
Bristol-Myers declined to comment.
Wellington — which is Bristol's largest institutional holder with 135.3 million shares, or 8 percent, of its common stock — said Wednesday the Celgene deal asks Bristol shareholders to accept too much risk. Starboard,which holds about 1 million shares, cited similar concerns in an open letter to shareholders Thursday, saying the Celgene deal was "poorly conceived and ill-advised."
Brian Skorney, senior research analyst at Robert W. Baird & Co, said it's unusual for an investment firm like Wellington, which has some gravitas with shareholders, to come out against such a deal.
"Wellington in of itself is huge in the bio-pharmaceutical space. They're a major voice in terms of long-term shareholders," Skorney told CNBC. "Now the question is does [Wellington's opposition] bring more shareholders away who would otherwise vote with Bristol?"
Buying Celgene was seen as giving Bristol more cancer drugs at a time when its immuno-oncology portfolio struggles to keep up with rival Merck's. Bristol's blockbuster Opdivo, which boosts the immune system to attack cancer, has fallen behind its leading competitor, Merck's Keytruda.
Brad Loncar, CEO of Loncar Investments, said there was a feeling among investors that Bristol's management and stock performance aren't strong enough to execute a deal as big as Celgene. Bristol's shares have slid 21 percent over the last 12 months. Shares of Merck, which he said has managed to "outclass" Bristol, have soared almost 50 percent in the same period.
"I talked to a lot of people and I'm not aware of any Bristol shareholders who were excited and even for the deal. Literally, not one," Loncar said.
Shares of Bristol rose by about 1.4 percent Thursday, following the opposition from Wellington and Starboard, while Celgene shares fell by about 8.7 percent.
On Thursday, following Starboard's announced opposition, Bristol said that it "welcomes the opinions of all of its stockholders and will review Starboard's letter and respond in due course."
"The Bristol-Myers Squibb Board and management team are confident that our combination with Celgene will create a premier biopharma company and deliver substantial benefits to our stockholders," they added.
-- Join us in New York City on May 21, when we'll explore some of these topics and more on stage with United Therepeautics CEO Martine Rothblatt, Novartis CEO Vasant Narasimhan, Johnson & Johnson CEO Alex Gorsky and more at our Healthy Returns Conference.